Maryland House Bill HB1423

Maryland 2024 Regular Session

• Introduced: 2/9/24
• Refer: 2/9/24

Caption

Maryland Medical Assistance Program and Health Insurance - Step Therapy, Fail-First Protocols, and Prior Authorization - Prescription Drugs to Treat Serious Mental Illness

Impact

This legislation is poised to provide significant relief for individuals suffering from serious mental illnesses by ensuring that they have more immediate access to necessary medications. This step is viewed as critical due to the often-detrimental impact that delays in receiving appropriate treatment can have on the mental health outcomes of affected individuals. The bill directs the Maryland Department of Health to monitor the cost implications for the Medical Assistance Program over the coming years to assess any financial impacts stemming from this change.

Summary

House Bill 1423 is a legislative proposal aimed at reforming the process surrounding the prescription of medications for serious mental illnesses. Specifically, it seeks to eliminate barriers created by prior authorization requirements, fail-first protocols, and step therapy protocols that insurers often impose. The bill would apply these changes to the Maryland Medical Assistance Program as well as to various health insurers, including nonprofit health service organizations and managed care entities. By July 1, 2024, the bill mandates that no authorization requirement or step therapy for prescription drugs be applied for treatments concerning conditions like bipolar disorder, schizophrenia, major depression, and post-traumatic stress disorder (PTSD).

Contention

While generally seen as a positive step toward improving mental health care, the bill has faced specific points of contention. Critics may argue that removing prior authorizations and step therapy could result in increased costs for insurance providers, potentially leading to higher premiums for consumers. Furthermore, some healthcare professionals and stakeholders might express concerns regarding the appropriate use of medications without oversight that prior authorization processes sometimes provide. Balancing effective treatment access against cost management represents an ongoing challenge in the framework of this bill.